You are here

Scientists Say Some Activities Might Slow Cognitive Decline

Physical activity, blood pressure control, cognitive training all help

Researchers say certain behaviors can prevent cognitive decline. People who stay physically active, control their blood pressure, and partake in cognitive training stand a better chance of staving off dementia than those who don’t, according to a report by the National Academies of Sciences, Engineering, and Medicine. (Cognitive training entails interventions that enhance memory, reasoning, or how fast someone can identify visual information on a screen.)

This is groundbreaking because seven years ago a study by the Agency for Healthcare Research and Quality could not find any activities that might stave off or slow down cognitive decline.

Researchers of the latest study are quick to point out that this is far from the final word on the subject. “Before developing public health strategies that strongly encourage the adoption of cognitive training, blood pressure management, and increased physical activity for the purpose of maintaining cognitive function, additional research is needed to further understand and gain confidence in the effectiveness of these interventions,” the report states.

On the other hand: “The fact that the report does not strongly support a public health campaign focused on actively promoting adoption of any type of intervention should not be taken to reflect a lack of progress or prospects for preventing or delaying the discussed conditions.”

Source: National Academies of Sciences, Engineering, and Medicine; June 22, 2017.

Recent Headlines

Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Beagles Beat Out Advanced Technology
Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission